Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05288361 · ClinicalTrials.gov registry record
The DISCOVER INOCA Prospective Multi-center Registry
A clinical trial of Endothelial Dysfunction and Coronary Microvascular Dysfunction, sponsored by Yale University.
- Active
- Registry status
- 500
- Enrollment target
- 9
- Study locations
NCT05288361: Active study of Endothelial Dysfunction and Coronary Microvascular Dysfunction, sponsored by Yale University.
NCT05288361 is a study of Endothelial Dysfunction and Coronary Microvascular Dysfunction that is active but no longer recruiting, run by Yale University. The registered enrollment target is 500 participants, above the 81-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (517% higher). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05288361, a study of Endothelial Dysfunction and Coronary Microvascular Dysfunction, is active but no longer recruiting, sponsored by Yale University.
- ACTIVE NOT RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 9
- Study locations
Study Summary
The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
Primary Outcome
The following phenotypes will be captured: Coronary microvascular dysfunction (CMD)- Criteria for a diagnosis of CMD include an abnormal Index of Microcirculatory Resistance (IMR) ≥ 25 and/or impaired Coronary Flow Reserve (CFR) ≤ 2.0; Vasospastic angina (VSA): Includes coronary vasospasm, microvascular spasm, and endothelial dysfunction. Criteria for coronary vasospasm include ≥ 90% narrowing of the epicardial vessel during acetylcholine testing and either or both angina and transient ischemic
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Study Locations (9)
New York
- New York Presbyterian-Brooklyn Methodist Hospital - Brooklyn
- NYU Langone Health - New York
- Columbia University Irving Medical Center - New York
California
- UCLA Health - Los Angeles
- Stanford Hospital - Stanford
Connecticut
- Yale New Haven Hospital - New Haven
Georgia
- Northeast Georgia Medical Center - Gainesville
Ohio
- The Christ Hospital - Cincinnati
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2022-09-14 |
| Est. Completion | 2032-12-31 |
What the registry record for NCT05288361 still lists
NCT05288361 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 45 other Endothelial Dysfunction trials with a reported enrollment target (517% higher).
The record links to 6 conditions, with Endothelial Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire is the first listed.
NCT05288361 lists 9 locations in 6 states (New York, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT05288361 about?
NCT05288361 is a clinical study titled "The DISCOVER INOCA Prospective Multi-center Registry". The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.
What is the current status of trial NCT05288361?
This trial is currently active not recruiting. The enrollment target is 500 participants. The study started on 2022-09-14. Estimated completion is 2032-12-31.
What conditions does trial NCT05288361 study?
This clinical trial studies the following conditions: Endothelial Dysfunction, Coronary Microvascular Dysfunction, Microvascular Angina, Ischemia and No Obstructive Coronary Artery Disease, Coronary Vasospasm.
What interventions are being tested in trial NCT05288361?
The interventions under investigation include: Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05288361?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05288361 being conducted?
This trial has 9 study locations across California, Connecticut, Georgia, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endothelial Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05288361's enrollment target sits among peer trials
500 2nd of 45 the highest of 45 other Endothelial Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endothelial Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Effect of a Daily Supplement on Plasma PAI-1 Levels
RECRUITING · Phase 1
-
Role of Endothelial Function in SCI CVD Risk
RECRUITING
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Role of ET-1, Physical Activity, and Sedentary Behavior in Microvascular Dysfunction Following GDM
RECRUITING · Early Phase 1
-
B-Complex: A Nutraceutical SANS Countermeasure
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI